G1 Therapeutics, a clinical-stage biotech developing novel therapeutics for cancer, raised $105 million by offering 7 million shares at $15, the low end of the range of $15 to $17. G1 originally planned to offer 6.25 million shares at the same range. At the offer price, G1 commands a market value of $460 million. G1 Therapeutics plans to list on the Nasdaq under the symbol GTHX. J.P. Morgan and Cowen & Company acted as lead managers on the deal.
